title: Development of acromegaly in patients with prolactinomas.
abstract: OBJECTIVE
  Patients with prolactinomas and patients with acromegaly often have heterogenous adenomas. In this study we have focused on patients with prolactinomas who developed acromegaly and acromegalic patients with hyperprolactinaemia. Our hypothesis is that some patients with hyperprolactinaemia may develop clinical acromegaly.
  
  
  METHODS
  We have included patients examined at department M, Odense University Hospital between 1996 and 2001. Seventy-eight patients with prolactinomas, 65 females and 13 males, with a median age (range) of 30 Years (14-74) and 47 Years (20-66), respectively, were included in the study.
  
  
  RESULTS
  In females and males the median prolactin (PRL) levels were 90 microg/l (27-4700; normal values (NV) <or=23) and 1075 microg/l (24-6500; NV <or=14), respectively. The PRL levels were significantly higher in males compared with females (P<0.002). Fifty-nine patients with acromegaly, 24 females and 35 males, with a median age (range) of 45 Years (24-70) and 53 Years (19-70), respectively, were included. Seven of the 24 females had hyperprolactinaemia, with PRL levels of 90 microg/l (27-494). Thirteen of the 35 males had hyperprolactinaemia with PRL levels of 47 microg/l (17-251). Three females with prolactinomas developed acromegaly clinically and biochemically. These patients had a normal low GH level and/or a normal IGF-I level at first diagnosis.
  
  
  CONCLUSIONS
  Our findings suggest that there is a common group of patients with a pituitary adenoma who secrete PRL and GH unsynchronously. Some of these patients have clinical acromegaly at diagnosis and some patients diagnosed as prolactinomas will develop acromegaly. We suggest an annual IGF-I measurement as a screening test.
authors.affiliation: Department of Endocrinology, Odense University Hospital, 5000 Odense C, Denmark. M.Andersen@dadlnet.dk
authors.forename: Marianne
authors.initials: M
authors.lastname: Andersen
authors.forename: Casper
authors.initials: C
authors.lastname: Hagen
authors.forename: Jan
authors.initials: J
authors.lastname: Frystyk
authors.forename: Henrik Daa
authors.initials: HD
authors.lastname: Schroeder
authors.forename: Claus
authors.initials: C
authors.lastname: Hagen
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000453:epidemiology*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000453:epidemiology*; D012307:Risk Factors; D017678:Sex Distribution
chemical_list: D007334:Insulin-Like Growth Factor I; D011388:Prolactin